Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have been observed in several large cardiovascular outcome trials to significantly reduce the incidence of major cardiovascular event (MACE) with type 2 diabetic patients. The clinical trials of GLP-1 RAs, including lixisenatide, exenatide, liraglutide, semaglutide, albiglutide, and dulaglutide, are associated with a significantly 14% lower risk of MACE in patients with T2DM and a history of CV disease, and with a nonsignificantly 6% lower risk in patients without history of CV disease. Some of the interpretation with GLP-1 RA trials suggested the possible role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in primary prevention of cardiovascular diseases in nondiabetic individual, echoed by a recent editorial redefining the role of GLP-1 RAs being beyond glycaemic control. The narrative review provides an in-depth insight into GLP-1 RA use guideline in different countries and regions of the world and examines the safety and concern of GLP-1 RA use. The narrative review draws the comparison of GLP-1 RA use between diabetic and nondiabetic individual in terms of cardiovascular and metabolic benefits and points out the direction of future clinical trials of GLP-1 RAs in nondiabetic individuals. The focus of the review is on GLP-1 RAs’ preventive roles in nondiabetic individuals with cardiovascular disease, chronic kidney diseases, obesity, dyslipidaemia, hypertension, nonalcoholic fatty liver diseases, polycystic ovarian syndrome (PCOS), and perioperative complications of bariatric surgery, albeit in small studies and subset analysis of clinical trials of diabetic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 2×
“Both drugs also induced a slower rate of eGFR decline [18, 19].”
BackgroundResultSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003583 · Cited by 5,148
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763 · cited 1×
“GLP-1 RAs can be indicated with or without metformin and are recommended in T2DM patients with CVD risk or CKD without albuminuria or those who need assistance for weight loss in the USA [12], in Australia [13], in European Union [14], in United Kingdom [15], and in China [16].”
BackgroundDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“and secretion, decrease glucagon secretion, increase glucose uptake and glycogen synthesis in peripheral tissues, delay gastric emptying, and increase satiety [5], making it an ideal target for diabetes therapy.”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“GLP-1 RAs have its unique mechanism of action of simultaneously increasing insulin secretion and inhibiting glucagon only in response to increased glucose levels [7, 8] and can potentially be used in obese and nondiabetic individuals without the risk of hypoglycaemia [9].”
BackgroundA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 3×
“In ELIXA, lixisenatide reduced urinary albumin-to-creatinine ratio; although correction for glycaemic control decreased significance, diminished the incidence of macroalbuminuria, remaining unattenuated when corrected for HbA1c, and did not affect eGFR decline [20].”
BackgroundResultArmstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
Research works printed but not linked: 38
- 10.1016/S0140-6736(87)91194-9 · DOI · Paper page
- 10.15277/bjdvd.2015.011 · DOI
- 10.1007/s13410-020-00879-4 · DOI
- Australian Medicine Handbook (AMH), 2022, Glucagon -like peptide analogues Australian Medicines Handbook
- Nice, 2015, Type 2 diabetes in adults: management
- 10.3760/cma.j.cn112138-20200704-00646 · DOI
- 10.1002/dmrr.3158 · DOI · Paper page
- 10.1056/NEJMoa1612917 · DOI · Paper page
- 10.1016/S0140-6736(19)31149-3 · DOI · Paper page
- 10.1056/NEJMoa1901118 · DOI · Paper page
- 10.1016/S0735-1097(18)31214-2 · DOI
- 10.1016/j.ahj.2015.07.014 · DOI
- 10.1007/s12020-015-0798-0 · DOI
- 10.1210/jc.2011-0585 · DOI · Paper page
- 10.1111/obr.12113 · DOI · Paper page
- 10.1136/bmj.g2646 · DOI · Paper page
- 10.1080/14656566.2019.1695779 · DOI · Paper page
- 10.2147/DDDT.S58459 · DOI · Paper page
- 10.1080/13543776.2020.1811851 · DOI · Paper page
- 10.1159/000521264 · DOI · Paper page
- 10.1016/S0140-6736(18)31773-2 · DOI · Paper page
- 10.1016/j.jpeds.2021.05.009 · DOI · Paper page
- 10.1016/j.atherosclerosis.2018.03.027 · DOI
- 10.1371/journal.pone.0135329 · DOI · Paper page
- 10.1111/1753-0407.12555 · DOI · Paper page
- 10.3389/fendo.2021.609110 · DOI · Paper page
- 10.1016/j.rbmo.2019.04.017 · DOI · Paper page
- 10.1016/j.metabol.2017.10.014 · DOI
- 10.1210/en.2017-00564 · DOI · Paper page
- 10.1016/S2213-8587(19)30157-3 · DOI · Paper page
- 10.1089/dia.2014.0188 · DOI · Paper page
- 10.1177/11795514211051697 · DOI · Paper page
- 10.1055/a-0818-6374 · DOI · Paper page
- 10.1111/j.1464-5491.2010.03020.x · DOI · Paper page
- 10.1111/dom.12414 · DOI · Paper page
- 10.1900/RDS.2014.11.202 · doi:10.1900/rds.2014.11.202
- 10.1111/dom.12386 · DOI · Paper page
- 10.1111/dom.12297 · DOI
Cited by
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Wong, H. J., Sim, B., Teo, Y. H., Teo, Y. N., Chan, M. Y., Yeo, L. L. L., Eng, P. C., Tan, B. Y. Q., Sattar, N., Dalakoti, M., et al. (2025) · Diabetes Care · doi:10.2337/dc24-1678 · Cited by 208
Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review
Gofron, K. K., Wasilewski, A., & Małgorzewicz, S. (2025) · Nutrients · doi:10.3390/nu17081303 · Cited by 90
Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies
Szczesnowicz, A., Szeliga, A., Niwczyk, O., Bala, G., & Meczekalski, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185915 · Cited by 83
“A trial including 150 women with PCOS with impaired fasting glucose and/or impaired glucose tolerance demonstrated a prediabetes remission rate of 64% with combined treatment, 56% with exenatide only, and 32% with metformin only [65].”
BackgroundMilder, D. A., Milder, T. Y., Liang, S. S., & Kam, P. C. A. (2024) · Anaesthesia · doi:10.1111/anae.16306 · Cited by 62
“The `incretin effect´ of GLP-1 receptor agonists was fi rst described when an oral glucose load was shown to produce a proportionally greater and sustained release of insulin compared with an equivalent dose of intravenous glucose [12, 13].”
Metadata
- Authors
- Xu, D., Nair, A., Sigston, C., Ho, C., Li, J., Yang, D., Liao, X., Chen, W., Kuang, M., Li, Y., Reid, C., & Xiao, H.
- Venue
- Cardiovascular Therapeutics
- Publisher
- Wiley
- Published
- 2022-11-16
- Volume
- 2022
- Pages
- 1-9
- ISSN
- 1755-5914 (ISSN-L)
- 1755-5922
- OpenAlex
- W4309323048
- Cited by
- 50
- References
- 41
- FWCI
- 6.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations. https://app.cochat.ai/papers/10.1155/2022/6820377
- The paper
- Xu, D., Nair, A., Sigston, C., Ho, C., Li, J., Yang, D., Liao, X., Chen, W., Kuang, M., Li, Y., Reid, C., & Xiao, H. (2022). Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations. Cardiovascular Therapeutics. https://doi.org/10.1155/2022/6820377
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.